• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 P.M. Eastern Time

    11/18/24 8:30:00 AM ET
    $BHST
    Get the next $BHST alert in real time by email

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 18, 2024) - BioHarvest Sciences Inc. (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2024 after market close on Monday, November 25, 2024.

    Management will host an investor conference call at 4:30 p.m. Eastern time on Monday, November 25, 2024, to discuss BioHarvest's third quarter 2024 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:

    Third Quarter FY2024 Results Conference Call
    Date: Monday, November 25, 2024
    Time: 4:30 p.m. Eastern time
    U.S./Canada Dial-in: 1-844-825-9789
    International Dial-in: 1-412-317-5180
    Conference ID: 10194495
    Webcast: BHST Q3 FY2024 Earnings Conference Call

    Please dial in at least 10 minutes before the start of the call to ensure timely participation.

    A telephone playback of the call will be available through Monday, December 9, 2024. To listen, call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 10194495. A webcast replay will also be available by clicking here: BHST Q3 FY2024 Earnings Conference Call.

    About BioHarvest Sciences Inc.

    BioHarvest Sciences Inc. (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

    Forward-Looking Statements

    Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

    Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

    This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

    BioHarvest Corporate Contact:
    Dave Ryan, VP Investor Relations & Director
    +1 (604) 622-1186
    [email protected]

    Investor Relations Contact:
    Lucas A. Zimmerman
    Managing Director
    MZ Group - MZ North America
    +1 (949) 259-4987
    [email protected]

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230394

    Get the next $BHST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHST

    DatePrice TargetRatingAnalyst
    5/5/2025$15.00Buy
    Craig Hallum
    12/18/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $BHST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on BioHarvest Sciences with a new price target

      Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

      5/5/25 8:30:45 AM ET
      $BHST
    • Maxim Group initiated coverage on BioHarvest Sciences with a new price target

      Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

      12/18/24 8:10:03 AM ET
      $BHST

    $BHST
    Leadership Updates

    Live Leadership Updates

    See more
    • BioHarvest Announces Appointment of Sharon Malka to Board of Directors

      Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

      1/22/25 8:30:00 AM ET
      $BHST

    $BHST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound

      First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis ProcessRehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.Ahead of the sig

      5/21/25 8:30:00 AM ET
      $BHST
    • Diamond Equity Research Releases Update Note on BioHarvest Sciences Inc. (NASDAQ: BHST)

      New York, May 21, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on BioHarvest Sciences Inc. (NASDAQ:BHST). The update note includes detailed information on the BioHarvest Sciences' financial results, operational updates, business model, management commentary, valuation, and risks. The update note is available below. BioHarvest Sciences May 2025 Update Note  Highlights from the note include:       Q1 Results Surpass Expectations on VINIA Strength and Operating Efficiencies:  BioHarvest Sciences reported robust financial performance for the first quarter of 2025, with rev

      5/21/25 8:00:00 AM ET
      $BHST
    • BioHarvest Sciences Reports First Quarter 2025 Financial Results

      First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

      5/15/25 4:05:00 PM ET
      $BHST

    $BHST
    SEC Filings

    See more
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/21/25 2:48:39 PM ET
      $BHST
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/15/25 4:49:56 PM ET
      $BHST
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/15/25 4:26:58 PM ET
      $BHST

    $BHST
    Financials

    Live finance-specific insights

    See more
    • BioHarvest Sciences Reports First Quarter 2025 Financial Results

      First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

      5/15/25 4:05:00 PM ET
      $BHST
    • BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time

      Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter

      5/1/25 8:30:00 AM ET
      $BHST
    • BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 MillionCDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based SweetenersRehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024.Fourth Quarter 2024 & Subsequent Operational HighlightsAll figures stated in this news release are in U.S.

      3/31/25 4:05:00 PM ET
      $BHST